NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Quetiapine for the treatment of generalised anxiety disorder

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
AstraZeneca (quetiapine)	Board of Community Health Councils in Wales
Patient/carer groups	British National Formulary
Afiya TrustAnxiety Alliance	Commissioning Support Appraisals Service
Anxiety Care	Department of Health, Social Services
Anxiety UK	and Public Safety for Northern Ireland
Black Health Agency	Hafal
Black Mental Health UK	 Medicines and Healthcare products
CALM – Campaign Against Living	Regulatory Agency
Miserably	Mental Health Act Commission
• Changes	MIND Cymru
Chinese Mental Health Association	National Association of Primary Care National Leading to Manual Line III.
 Chinese National Healthy Living Centre 	 National Institute for Mental Health in England
Combat Stress	 National Public Health Service for
Confederation of Indian Organisations	Wales
Counsel and Care	NHS Alliance
Diverse Minds	NHS Confederation
Equalities National Council	NHS Purchase and Supply Agency
First Steps to Freedom	NHS Quality Improvement Scotland
Mental Health Foundation	Scottish Medicines Consortium
Mental Health Matters	Descible comparator manufacturare
Mental Health Providers Forum	Possible comparator manufacturersActavis (diazepam, paroxetine,
• MIND	venlafaxine)
Muslim Council of Great Britain	Almus Pharmaceuticals (diazepam,
Muslim Health Network	lorazepam)
Rethink SANE	Arrow Generics (diazepam, lorazepam,)
• SANE	The Boots Company (diazepam)
SIRISouth Asian Health Foundation	Dallas Burston Ashbourne (venlafaxine)
	 Doncaster Pharmaceuticals (diazepam,
Specialised Healthcare AllianceTogether	venlafaxine)
Turning Point	Dr Reddys Labs (diazepam)
UK Advocacy Network	Durbin (diazepam)
- Ortharoday Notwork	Forum Products (venlafaxine)

National Institute for Health and Clinical Excellence Provisional matrix for the technology appraisal of quetiapine for the treatment of generalized anxiety disorder Issue date: November 2009 Page 1 of 4

Consultees Commentators (no right to submit or appeal) United Response Genus Pharmaceuticals (paroxetine) GlaxoSmithKline (paroxetine) Professional groups Goldshield (venlafaxine) British Association for Counselling and Hameln Pharmaceuticals (diazepam) Psychotherapy IVAX Pharmaceuticals (diazepam, British Association for paroxetine) Psychopharmacology Kent Pharmaceuticals (diazepam, British Association for Services to the lorazepam, paroxetine, venlafaxine) **Elderly** Media Innovations (computerised British Association of Behavioural and cognitive behavioural therapy) Cognitive Psychotherapies Mental health foundation (computerised British Association of cognitive behavioural therapy) **Psychotherapists** Mylan (diazepam, lorazepam, British Confederation of paroxetine, venlafaxine) **Psychotherapists** Ranbaxy (diazepam, paroxetine, **British Geriatrics Society** venlafaxine) **British Neuropsychiatry Association** Ratiopharm (venlafaxine) **British Psychological Society** Relonchem (diazepam) Counsellors and Psychotherapists in Sandoz (diazepam, lorazepam, **Primary Care** paroxetine, venlafaxine) Mental Health Nurses Association Sigma Pharmaceuticals (diazepam, Primary Care Mental Health Education lorazepam, paroxetine, venlafaxine) Royal College of General Practitioners ST Solutions (Fear Fighter, Royal College of Nursing computerised cognitive behavioural therapy) Royal College of Pathologists Teva (diazepam, lorazepam, Royal College of Physicians paroxetine, venlafaxine) Royal College of Psychiatrists Ultrasis (computerised cognitive Royal Pharmaceutical Society behavioural therapy) Royal Society of Medicine -Intellectual Disabilities Forum Relevant research groups Sainsbury Centre for Mental Health Institute of Psychiatry United Kingdom Clinical Pharmacy MRC Clinical Trials Unit Association National Institute for Health Research United Kingdom Council for National Primary Care Research & **Psychotherapy Development Centre** United Kingdom Psychiatric Pharmacy Policy Research Institute on Ageing Group and Ethnicity Research Institute for the Care of Older Others People Department of Health NHS Sefton South West Essex Teaching PCT **Evidence Review Group** Welsh Assembly Government Evidence Review Group tbc National Institute for Health Research Health Technology Assessment

National Institute for Health and Clinical Excellence Provisional matrix for the technology appraisal of gu

Provisional matrix for the technology appraisal of quetiapine for the treatment of generalized anxiety disorder Issue date: November 2009 Page 2 of 4

Consultees	Commentators (no right to submit or appeal)
	Programme
	Associated Guideline GroupsNational Collaborating Centre for Mental Health
	Associated Public Health Groups • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.